Novartis

Overview

Pharmaceutical leader in radiopharmaceuticals via Pluvicto for prostate cancer, having invested tens of billions in supply chain infrastructure and providing the only existing playbook for global radiopharmaceutical delivery. Novartis is the only large company with a radiopharmaceutical product delivery playbook globally, having invested tens of billions of dollars in supply chain infrastructure for Pluvicto, yet still struggled with supply chain challenges in its early years. Novartis's Pluvicto has made major inroads into prostate cancer treatment and is described as transforming the standard of care for prostate cancer. (Segment 5 (20:00-25:00))